IP Library Patent Application 11756582
Patent Application
App. No. 11/756,582

Particle Fraction Determination of A Sample

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/756,582
Abstract

The present invention provides a device, test cards, methods and kits which are useful for determining the particle fraction and rate of viscosity of a fluid sample, the presence of an analyte in a fluid sample, or the aggregation of particles in a fluid sample to detect an analyte or as an immunologic assay.

Claims (74)

1 . A method for determining a particle fraction of a fluid sample comprising the step of: measuring impedance or resistance of said fluid sample, wherein said fluid sample volume is up to 20 μL.

2 . The method of claim 1 , further comprising the step of applying an AC or DC electric potential to said fluid sample.

3 . The method of claim 1 , wherein said particle fraction is hematocrit.

4 . The method of claim 1 , wherein said measuring step comprising the step of correlating said impedance measurement to a calibration standard curve to produce an impedance correlation.

5 . The method of claim 4 , wherein said impedance correlation is further processed into an output result corresponding to the particle fraction of said fluid sample.

6 . The method of claim 1 , wherein said fluid sample comprises a body fluid.

7 . The method of claim 6 , wherein said body fluid comprises blood.

8 . The method of claim 1 , wherein said fluid sample is of a non-bodily fluid.

9 . The method of claim 1 , wherein said fluid sample comprises water.

10 . A method for determining particle fraction of a fluid sample comprising the step of: applying said fluid sample to a chamber having volume up to 2 μL; and measuring an impedance or resistance of said fluid sample in said chamber.

11 . The method of claim 10 , further comprising the step of applying an AC or DC electric potential to said fluid sample.

12 . The method of claim 10 , wherein said particle fraction is hematocrit.

13 . The method of claim 10 , wherein said measuring step further comprises correlating said impedance or resistance measurement to a calibration standard curve to produce an impedance or resistance correlation.

14 . The method of claim 13 , further comprising processing said impedance or resistance correlation into an output result corresponding to the particle fraction of said fluid sample.

15 . The method of claim 10 , wherein said fluid sample comprises a body fluid.

16 . The method of claim 15 , wherein said body fluid comprises blood.

17 . The method of claim 10 , wherein said fluid sample is a non-bodily fluid.

18 . The method of claim 10 , wherein said fluid sample is water.

19 . A method for determining particle fraction of a fluid sample comprising the step of measuring electrical properties of said fluid sample, wherein said measuring step is used to determine said particle fraction, and wherein said fluid sample volume is up to 2 μL.

20 . The method of claim 19 , further comprising applying AC electric potential to said fluid sample.

21 . The method of claim 19 , further comprising applying DC electric potential to said fluid sample.

22 . The method of claim 19 , wherein said particle fraction is hematocrit.

23 . The method of claim 19 , wherein said measuring step further comprises:

(a) measuring impedance at one or more time points of said fluid sample and correlating said impedance to a particle fraction calibration standard curve to produce a first impedance correlation;

(b) measuring rate of change of impedance over time of said fluid sample and correlating said impedance to a coagulation calibration standard curve to produce a second impedance correlation; and

(c) processing said first and second impedance correlations into output results corresponding to the particle fraction and viscosity of said fluid sample.

24 . The method of claim 19 , wherein said fluid sample comprises a body fluid.

25 . The method of claim 24 , wherein said body fluid comprises blood.

26 . The method of claim 19 , wherein said chamber comprises one or more reagents for accelerating the coagulation of a fluid sample upon contact with said fluid sample.

27 . The method of claim 26 , wherein said reagents comprise reagents for prothrombin time, activated clotting time, activated partial prothrombin time, or thrombin clotting time.

28 . A method of determining particle fraction and viscosity of a fluid sample comprising the steps of:

a) applying said fluid sample to a first chamber having volume up to 2 μL and a second chamber having volume up to 2 μL wherein the first chamber further comprises one or more reagents for accelerating a coagulation of a fluid sample upon contact with said fluid sample;

b) measuring impedance of said fluid sample at one or more time points in the second chamber and correlating the impedance to a particle fraction calibration standard curve to produce a first impedance correlation;

c) measuring a rate of change of measured impedance over time of said fluid sample in said first chamber and correlating said impedance to a rate of coagulation calibration standard curve to produce a second impedance correlation; and

d) processing said first and second impedance correlations into output results corresponding to a particle fraction and viscosity of said fluid sample.

29 . The method of claim 28 , further comprising applying AC electric potential to said fluid sample.

30 . The method of claim 28 , wherein said particle fraction is hematocrit.

31 . The method of claim 28 , wherein said fluid sample comprises a body fluid.

32 . The method of claim 31 , wherein said body fluid comprises blood.

33 . A method for determining the amount or presence of analyte in a fluid sample comprising measuring change of impedance or resistance of said fluid sample in a chamber wherein chamber comprises a binding moiety that selectively binds to said analyte and wherein volume of said chamber is up to 2 μL.

34 . The method of claim 33 , wherein said determining step comprises

a) applying AC or DC electric potential to said chamber;

b) measuring impedance or resistance at two or more intervals;

c) correlating said change of impedance or resistance to an analyte calibration standard curve; and

d) processing said impedance correlations into output results corresponding to the amount or presence of said analyte of said fluid sample.

35 . The method of claim 33 , wherein said analyte is mammalian cells, microbial cells, drugs, chemical compounds, hormones, proteins, and immunoglobulins.

36 . The method of claim 35 , wherein said binding moiety is immunoglobulins, monoclonal antibodies, avidin, compromised avidin, streptavidin, lectins, protein A, haptens, biotin, iminobiotin, or sugars.

37 . The method of claim 35 , wherein said binding moiety is coupled to a substrate.

38 . The method of claim 37 , wherein said substrate is latex beads, whole blood cells, erythrocytes, white blood cells, platelets, colloidal gold particles, magnetic particles, quantum dots, bacteria, viral particles, or liposomes.

39 . A method for determining the amount or presence of analyte in a fluid sample, wherein said determining step comprises:

a) applying said fluid sample to two chambers, said chambers having volume up to 2 μL, wherein a first chamber comprises a binding moiety for agglutinating an analyte in a fluid sample upon contact with said fluid sample and a second chamber does not comprise said binding moiety;

b) applying AC or DC electric potential to said first and second chambers;

c) measuring the difference in impedance or resistance of said fluid sample in said first and second chambers at one or more intervals;

d) correlating said difference in impedance or resistance to an analyte calibration standard curve to produce an impedance correlation; and

e) processing said impedance or resistance correlation into output results corresponding to the amount or presence of said analyte of said fluid sample.

40 . The method of claim 39 , wherein said analyte is mammalian cells, microbial cells, drugs, chemical compounds, hormones, proteins, and immunoglobulins.

41 . The method of claim 39 , wherein said binding moiety is immunoglobulins, monoclonal antibodies, avidin, compromised avidin, streptavidin, lectins, protein A, haptens, biotin, iminobiotin, or sugars.

42 . The method of claim 39 , wherein said binding moiety is coupled to a substrate.

43 . The method of claim 42 , wherein said substrate is latex beads, whole blood cells, erythrocytes, white blood cells, platelets, colloidal gold particles, magnetic particles, quantum dots, bacteria, viral particles, or liposomes.

44 . A device for determining particle fraction, amount or presence of an analyte, and viscosity of a fluid sample comprising;

a) a detection unit adapted and configured to apply AC electric potential to said fluid sample and measure one or more impedance signals of said fluid sample;

b) a processor unit electrically connected to said detection unit adapted and configured to receive and convert said impedance signals into output results corresponding to said particle fraction, amount or presence of said analyte, or viscosity of said fluid sample.

45 . The device of claim 44 , wherein said processor unit separately determines said particle fraction, amount or presence of said analyte, or viscosity of said fluid sample from said impedance signals using assay calibration standard curve information stored in the processor.

46 . The device of claim 44 , wherein said particle fraction is hematocrit.

47 . The device of claim 44 , wherein said particle fraction is aggregated particles.

48 . The device of claim 44 , wherein said analyte is mammalian cells, microbial cells, drugs, chemical compounds, hormones, proteins, and immunoglobulins.

49 . The device of claim 48 , wherein said viscosity is rate of coagulation.

50 . A test card for determining a condition of a fluid sample comprising: an inlet port for receiving a fluid sample of less than 20 μL fluidly connected to two or more capillary channels wherein each capillary channel terminates in a fixed volume chamber having a volume up to 2 μL.

51 . The test card of claim 50 , wherein each of said chambers further comprises two electrodes for measurement of impedance in said fluid sample.

52 . The test card of claim 50 , wherein one or more said chambers further comprises one or more reagents for accelerating the coagulation of said fluid sample upon contact with said fluid sample.

53 . The test card of claim 50 , wherein one or more said chambers further comprises one or more binding moieties that selectively binds to an analyte.

54 . The test card of claim 53 , wherein said binding moiety is immunoglobulins, monoclonal antibodies, avidin, compromised avidin, streptavidin, lectins, protein A, haptens, biotin, iminobiotin, or sugars.

55 . The test card of claim 54 , wherein said binding moiety is coupled to a substrate.

56 . The test card of claim 55 , wherein said substrate is latex beads, whole blood cells, erythrocytes, white blood cells, platelets, colloidal gold particles, magnetic particles, quantum dots, bacteria, viral particles, or liposomes.

Assignments (8)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY RECORDED AT REEL 036994, FRAME 0192 AND REEL 037115, FRAME 0498 Recorded Oct 5, 2017
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS COLLATERAL AGENT
To: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
Reel/Frame 044213/0258 →
ASSIGNMENT OF IP SECURITY AGREEMENT, PREVIOUSLY RECORDED AT REEL 036994, FRAME 0192 Recorded Nov 16, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING ADMINISTRATIVE AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 037115/0498 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 29, 2015
From: ALERE CONNECT, LLC; ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.); ALERE SCARBOROUGH, INC. (FKA MATRITECH, INC. FKA ADVANTAGE DIAGNOSTICS CORP. OR FKA BINAX, INC. OR FKA MILANO ACQUISITION CORP.); INNOVACON, INC. (FKA APPLIED BIOTECH, INC. OR FKA AMEDITECH INC.); IONIAN TECHNOLOGIES, LLC (FKA IONIAN TECHNOLOGIES, INC.); QUALITY ASSURED SERVICES INC. (FKA ZYCARE INC.); STANDING STONE, LLC; ESCREEN, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 036994/0192 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL 026557 FRAME 0287 Recorded Jun 23, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
To: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL, INC.; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; MATRIA HEALTHCARE, INC.; ZYCARE, INC.
Reel/Frame 036011/0581 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ADVANTAGE DIAGNOSTICS CORPORATION; ALERE MEDICAL INCORPORATED; ALERE SAN DIEGO, INC.; ALERE SCARBOROUGH, INC.; AMEDITECH INC.; APPLIED BIOTECH, INC.; BINAX, INC.; BIOSITE INCORPORATED; CHOLESTECH CORPORATION; GENECARE MEDICAL GENETICS CENTER, INC.; HEMOSENSE, INC.; INSTANT TECHNOLOGIES, INC.; INVERNESS MEDICAL - BIOSTAR INC.; ISCHEMIA TECHNOLOGIES, INC.; MATRITECH, INC.; ZYCARE INC.; MARTIA HEALTHCARE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 026557/0287 →
SECURITY AGREEMENT Recorded Dec 12, 2007
From: HEMOSENSE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 020227/0892 →
SECURITY AGREEMENT Recorded Dec 10, 2007
From: HEMOSENSE, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 020218/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2007
From: GREENQUIST, ALFRED C.; MCINERNY, MARGARET
To: HEMOSENSE, INC.
Reel/Frame 019681/0347 →